CH Biotech R&D Co., Ltd. (TPE:6534)
Taiwan · Delayed Price · Currency is TWD 90.90
-0.40 (-0.44%)
Jun 5, 2026, 9:23 AM CST
CH Biotech R&D Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 491.3 | 464 | 476.39 | 463.29 | 465.42 | 291.5 |
Depreciation & Amortization | 216.12 | 212.63 | 188.47 | 164.34 | 138.51 | 95.33 |
Other Amortization | 1.49 | 1.49 | 1.29 | 1.48 | 1.18 | 1.32 |
Loss (Gain) From Sale of Assets | 0.6 | 0.52 | -0.31 | -1.07 | -0.57 | -0.11 |
Loss (Gain) on Equity Investments | 2.64 | 3.1 | 0.26 | 0.05 | - | - |
Stock-Based Compensation | - | - | - | 1.24 | - | - |
Provision & Write-off of Bad Debts | 11.19 | 11.19 | - | - | - | - |
Other Operating Activities | 17.44 | 8.44 | -65.57 | 43.98 | 13.03 | 41.05 |
Change in Accounts Receivable | 9.19 | -94.37 | -56.76 | -72.77 | 127.84 | -124.69 |
Change in Inventory | -56.6 | -33.56 | -1.7 | 52.96 | -54.46 | -82.64 |
Change in Accounts Payable | -2.66 | 0.21 | -2.66 | -0.36 | -11.09 | 13.94 |
Change in Unearned Revenue | -0.39 | -0.16 | -0.14 | 0.17 | -0.05 | -0.15 |
Change in Other Net Operating Assets | 26.45 | 15.54 | -0.81 | 5.85 | 19.17 | 28.81 |
Operating Cash Flow | 716.77 | 589.02 | 538.44 | 659.15 | 698.97 | 264.36 |
Operating Cash Flow Growth | 41.17% | 9.39% | -18.31% | -5.70% | 164.40% | 13.50% |
Capital Expenditures | -135.43 | -123.34 | -588.42 | -113.68 | -113.89 | -71.92 |
Sale of Property, Plant & Equipment | 0.22 | 0.3 | 0.32 | 2.61 | 1.23 | 0.23 |
Cash Acquisitions | - | - | -3.55 | - | - | - |
Sale (Purchase) of Intangibles | -6.57 | -4.23 | -1.54 | -1.04 | -3.26 | - |
Investment in Securities | - | - | - | -29.4 | - | - |
Other Investing Activities | -12.7 | -13.56 | -1.58 | -1.38 | -1.31 | 26.95 |
Investing Cash Flow | -154.48 | -140.84 | -594.77 | -142.89 | -117.22 | -44.75 |
Short-Term Debt Issued | - | 915 | 665.21 | 480 | 450 | 381 |
Long-Term Debt Issued | - | - | 413.3 | 475.6 | 595.6 | - |
Total Debt Issued | 50 | 915 | 1,079 | 955.6 | 1,046 | 381 |
Short-Term Debt Repaid | - | -840 | -570.17 | -410 | -518 | -436 |
Long-Term Debt Repaid | - | -184.49 | -546.51 | -620.69 | -776.34 | -124.85 |
Total Debt Repaid | -214.74 | -1,024 | -1,117 | -1,031 | -1,294 | -560.85 |
Net Debt Issued (Repaid) | -164.74 | -109.49 | -38.18 | -75.09 | -248.74 | -179.85 |
Issuance of Common Stock | 0.3 | 0.3 | 0.1 | - | - | - |
Common Dividends Paid | -421.48 | -421.48 | -369.05 | -473.77 | -126.63 | -42.21 |
Other Financing Activities | -0.46 | -0.41 | 0.92 | 442.26 | - | - |
Financing Cash Flow | -586.38 | -531.08 | -406.21 | -106.6 | -375.37 | -222.06 |
Foreign Exchange Rate Adjustments | -1.52 | -1.84 | 1.46 | 0.25 | 2.64 | -0.55 |
Net Cash Flow | -25.62 | -84.73 | -461.08 | 409.91 | 209.01 | -3 |
Free Cash Flow | 581.34 | 465.68 | -49.98 | 545.47 | 585.08 | 192.43 |
Free Cash Flow Growth | 84.93% | - | - | -6.77% | 204.04% | 53.91% |
Free Cash Flow Margin | 31.68% | 25.60% | -3.06% | 36.01% | 40.80% | 18.89% |
Free Cash Flow Per Share | - | 4.51 | -0.48 | 5.57 | 5.93 | 1.96 |
Cash Interest Paid | 16.95 | 16.95 | 14.98 | 17.41 | 16.19 | 13.87 |
Cash Income Tax Paid | 98.64 | 98.64 | 179.74 | 76.18 | 90.18 | 27.21 |
Levered Free Cash Flow | 654.15 | 359.89 | -201.89 | 446.3 | 411.22 | 111.1 |
Unlevered Free Cash Flow | 664.37 | 370.49 | -192.52 | 456.8 | 421.73 | 119.78 |
Change in Working Capital | -24.02 | -112.35 | -62.07 | -14.14 | 81.4 | -164.74 |